Disease control rate with axitinib/axitinib treatment

Axitinib/Axitinib (Axitinib) is a highly selective second-generation angiogenesis inhibitor mainly used for the treatment of advanced renal cell carcinoma (RCC). It blocks tumor blood vessel formation by inhibiting the vascular endothelial growth factor receptor (VEGFR) signaling pathway, thereby inhibiting tumor growth and spread. Due to its clear target, convenient oral dosage form, and clear indications, it has been widely used in the treatment of RCC in recent years.

"Disease control rate" (DCR) is a commonly used indicator to evaluate the clinical effect of anti-tumor drugs, usually referring to the sum of complete response (CR), partial response (PR) and stable disease (SD). Axitinib has shown high disease control rates in multiple international studies and real-world data, especially in patients with kidney cancer who have failed previous treatments.

Compared with first-generation tyrosine kinase inhibitors (such as sorafenib and sunitinib), axitinib has a more precise target and more completely inhibits the VEGFR family, so it has advantages in controlling disease progression. Most studies show that its DCR can reach more than 70%, and some combination immunotherapy regimens are even higher, which means that most patients' tumors can be maintained in a stable or shrinking state after receiving treatment.

In addition, axitinib has a rapid onset of action and a short metabolic cycle, which allows doctors to promptly adjust the dose or combine medications according to the patient's specific conditions. This controllability also helps maintain a stable state of the disease. Although its adverse reactions are common, such as hypertension, fatigue, hand-foot syndrome, etc., most of them can be managed through dose adjustment or supportive treatment, thereby extending the duration of the patient's medication and further improving the disease control rate.

In general, axitinib, as a targeted drug, has shown good disease control capabilities as a single agent or in combination with immunotherapy, and is currently a key treatment option for renal cell carcinoma, especially in advanced or recurrent cases.

Reference materials:https://en.wikipedia.org/wiki/Axitinib